Update Of Hepatitis C In Colombia

Keywords

Colombia; DAA; Direct-acting antiviral; HCV; Hepatitis C; South America

Abstract

Purpose of Review: The goal is to describe the epidemiology, disease burden and detection, available therapies, and current challenges to access care for people with chronic hepatitis C infection in Colombia. Recent Findings: There are no detailed statistics about the prevalence of HCV in Colombia; nonetheless, majority of patients with hepatitis C are infected with genotype 1 and having received blood products before 1996 represents the main risk factor. The use of intravenous drugs has started to be recognized as a population at risk that is in increment. Direct-acting antivirals became available in 2016 in Colombia thanks to a centralized purchase program with the Pan American Health Organization. Summary: There are well-established guidelines for the use of available antivirals for all disease stages and genotypes and sustained virologic response (SVR) rates are 95 to 100%. Underdiagnosis, access and linkage to care, and disease stigmatization have contributed to a low number of patients that have actually completed their therapy.

Publication Date

9-1-2018

Publication Title

Current Tropical Medicine Reports

Volume

5

Issue

3

Number of Pages

133-137

Document Type

Review

Personal Identifier

scopus

DOI Link

https://doi.org/10.1007/s40475-018-0147-5

Socpus ID

85047964975 (Scopus)

Source API URL

https://api.elsevier.com/content/abstract/scopus_id/85047964975

This document is currently not available here.

Share

COinS